ARTICLE SUMMARY:
China, India, and Singapore came out with the most medtech policy documents last month, as tracked by Pathways’ Document Depot, reflecting the robust efforts across Asia to forge new regulatory frameworks.
Docs of the Month is a regular column highlighting key findings from Pathway’s Document Depot, a database of global medtech regulatory and policy official documents, including rules, guidance documents, memos, white papers, and more from national authorities, non-governmental groups, and global organizations. Check out the database to access all items referenced below.
About half of the documents captured in August by Pathways’ Document Depot came from the regulatory agencies in just three countries: China, India, and Singapore. Not all of the 24 documents issued last month by China’s National Medical Products Administration (NMPA), India’s Central Drugs Standard Control Organization (CDSCO), and Singapore’s Health Sciences Authority (HSA) are of major significance, and some are simply updates to existing policies. But the scale of activity underscores what has been a consistent reality in recent years: Asia is a hotbed of regulatory reform, and, generally, that reform is moving in the direction of setting up more attractive, harmonized frameworks for medtech firms to leverage.
